Skip to main content
SpringerLink
Log in

Pharmacokinetics of isoniazid metabolism in man

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

Detailed pharmacokinetic studies undertaken on a slow and a rapid acetylator of isoniazid enabled approximate first-order rate constants to be calculated for the metabolic processes involved in the conversion of isoniazid to acetylisoniazid, isonicotinic acid, isonicotinylglycine, monoacetylhydrazine, and diacetylhydrazine, and their excretion in the urine. Further studies of the metabolism of isoniazid were carried out on another 17 slow and 11 rapid acetylators. The major pathway of isoniazid metabolism was acetylation. The rapid acetylators acetylated isoniazid 5–6 times more rapidly than the slow acetylators. Acid-labile hydrazones were also formed, and some isoniazid was hydrolyzed directly to isonicotinic acid. The major metabolic route for the formation of isonicotinic acid from isoniazid was via acetylisoniazid. Cleavage of acetylisoniazid in the body resulted in the formation of monoacetylhydrazine, which was then acetylated polymorphically to diacetylhydrazine in a manner analogous to the acetylation of isoniazid. Individuals differed in their ability to conjugate isonicotinic acid with glycine, and these differences were unrelated to the rates at which isoniazid was acetylated. The conjugation of isonicotinic acid with glycine and the acetylation of isoniazid appeared to be partially saturated in vivoafter the administration of doses of as little as 250 mg of either compound.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. W. Fox. General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis.Bull. Int. Union Tuberc. 47:49–67 (1972).

    CAS  PubMed  Google Scholar 

  2. W. Fox and D. A. Mitchison. Short course chemotherapy for pulmonary tuberculosis.Am. Rev. Resp. Dis. 111:325–352 (1975).

    CAS  PubMed  Google Scholar 

  3. D. A. P. Evans. Genetic variations in the acetylation of isoniazid and other drugs.Ann. N.Y. Acad. Sci. 151:723–733 (1968).

    Article  CAS  PubMed  Google Scholar 

  4. B. N. La Du. Isoniazid and pseudocholinesterase polymorphisms.Fed. Proc. 31:1276–1285 (1972).

    PubMed  Google Scholar 

  5. J. H. Peters. Genetic factors in relation to drugs.Ann. Rev. Pharmacol. 8:427–452 (1968).

    Article  CAS  PubMed  Google Scholar 

  6. G. A. Ellard. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.Clin. Pharmacol. Ther. (in press, 1976).

  7. G. A. Ellard and P. T. Gammon. The pharmacokinetics of isoniazid metabolism in man. In M. Hejzlar, M. Semonsky, and S. Masak (eds.),Advances in Antimicrobial and Anti-neoplastic Chemotherapy, Urban and Schwarzenberg, Munich, 1972, pp. 45–46.

    Google Scholar 

  8. G. A. Ellard, P. T. Gammon, and S. M. Wallace. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.Biochem. J. 126:449–458 (1972).

    CAS  PubMed Central  PubMed  Google Scholar 

  9. H. McKennis, Jr., A. S. Yard, J. H. Weatherby, and J. A. Hagy. Acetylation of hydrazine and the formation of 1,2-diacetylhydrazinein vivo.J. Pharmacol. Exp. Ther. 126:109–116 (1959).

    CAS  PubMed  Google Scholar 

  10. A. Viznerová, Z. Sláviková, and G. A. Ellard. The determination of the acetylator pheno-type of tuberculosis patients in Czechoslovakia using sulphadimidine.Tubercle 54:67–71 (1973).

    Article  PubMed  Google Scholar 

  11. D. A. P. Evans, P. B. Storey, and V. A. McKusick. Further observations on the determination of isoniazid inactivator phenotype.Bull. Johns Hopkins Hasp. 108:60–66 (1961).

    CAS  Google Scholar 

  12. G. A. Ellard, V. R. Aber, P. T. Gammon, D. A. Mitchison, S. Lakshminarayan, K. M. Citron, W. Fox, and R. Tall. Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis.Lancet 1:340–343 (1972).

    Article  CAS  PubMed  Google Scholar 

  13. G. A. Ellard, P. T. Gammon, and H. Tiitinen. Determination of the acetylator phenotype using matrix isoniazid.Tubercle 56:203–209 (1975).

    Article  CAS  PubMed  Google Scholar 

  14. H. Varley.Practical Clinical Biochemistry, 3rd ed., Heinemann, London, 1962, p. 634.

    Google Scholar 

  15. R. Gelber, P. Jacobsen, and L. Levy. A study of the availability of six commercial formulations of isoniazid.Clin. Pharmacol. Ther. 10:841–848 (1969).

    CAS  PubMed  Google Scholar 

  16. J. H. Peters, K. S. Miller, and P. Brown. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.J. Pharmacol. Exp. Ther. 150: 298–304 (1965).

    CAS  PubMed  Google Scholar 

  17. J. W. Jenne, F. M. MacDonald, and E. Mendoza. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and para-amino salicylic acid in man.Am. Rev. Resp. Dis. 84:371–378 (1961).

    CAS  PubMed  Google Scholar 

  18. J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971, Chap. 38, pp. 292–296.

    Google Scholar 

  19. A. J. Cummings, B. K. Martin, and G. S. Park. Kinetic considerations relating to the accrual and elimination of drug metabolites.Brit. J. Pharmacol. Chemother. 29:136–149 (1967).

    Article  CAS  Google Scholar 

  20. J. R. Mitchell, U. P. Thorgeirsson, M. Black, J. A. Timbrell, W. R. Snodgrass, W. Z. Potter, D. J. Jollow, and H. R. Keiser. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites.Clin. Pharmacol. Ther. 18:70–79 (1975).

    CAS  PubMed  Google Scholar 

  21. G. A. Ellard, P. T. Gammon, F. Polansky, A. Viznerová, I. Havlik, and W. Fox. Further studies on the pharmacology of a slow-release preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.Tubercle 54:57–66 (1973).

    Article  CAS  PubMed  Google Scholar 

  22. L. C. Dymond and D. W. Russell. Rapid determination of isonicotinic acid hydrazide in whole blood with 2,4,5-trinitrobenzenesulphonic acid.Clin. Chim. Acta 27:513–520 (1970).

    Article  CAS  PubMed  Google Scholar 

  23. H. G. Boxenbaum, G. S. Jodhka, A. C. Ferguson, S. Riegelman, and T. R. MacGregor. The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man.J. Pharmacokin. Biopharm. 2:211–237 (1974).

    Article  CAS  Google Scholar 

  24. G. Levy and L. P. Ansel. Kinetics of competitive inhibition of salicylic acid conjugation with glycine in man.Biochem. Pharmacol. 15:1033–1038 (1966).

    Article  CAS  PubMed  Google Scholar 

  25. J. H. Peters and V. E. Hayes. Comparative studies on the metabolism of isoniazid and isoniazid hydrazones in the dog.Arch. Int. Pharmacodyn. Ther. 159:328–339 (1966).

    CAS  PubMed  Google Scholar 

  26. F. Skrabal, R. N. Arnot, and G. F. Joplin. Equations for the prediction of normal values for exchangeable sodium, exchangeable potassium, extracellular fluid volume, and total body water.Brit. Med. J. 2:37–38 (1973).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. G. A. Ellard, P. T. Gammon, and H. Tiitinen. Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: A study in Finnish Lappland.Tubercle 54:201–210 (1973).

    Article  CAS  PubMed  Google Scholar 

  28. A. S. Yard and H. McKennis, Jr. Aspects of the metabolism of isoniazid and acetylisoniazid in the human and dog.J. Med. Pharm. Chem. 5:196–203 (1962).

    Article  CAS  PubMed  Google Scholar 

  29. J. W. Jenne. Partial purification and properties of the isoniazid transacetylase in human liver: Its relationship to the acetylation ofp-aminosalicylic acid.J. Clin. Invest. 44:1992–2002 (1965).

    Article  CAS  Google Scholar 

  30. W. W. Weber and S. N. Cohen. The mechanism of isoniazid acetylation by humanN- acetyltransferase.Biochim. Biophys. Acta 151:276–278 (1968).

    Article  CAS  PubMed  Google Scholar 

  31. W. W. Weber, S. N. Cohen, and M. S. Steinberg. Purification and properties ofN-acetyltransferase from mammalian liver.Ann. N.Y. Acad. Sci. 151:734–741 (1968).

    Article  CAS  PubMed  Google Scholar 

  32. L. H. Schmid. The problem of the rapid inactivator of isoniazid.Bull. Int. Union Tuberc. 32:487–502 (1962).

    Google Scholar 

  33. L. Eidus, M. M. Hodgkin, A. H. E. Hsu, and O. Schaeffer. Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation.Am. Rev. Resp. Dis. 110:34–42 (1974).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Research Council's Unit for Laboratory Studies of Tuberculosis, Royal Postgraduate Medical School, W12 0HS, London, England

    Gordon A. Ellard & Patricia T. Gammon

Authors
  1. Gordon A. Ellard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia T. Gammon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ellard, G.A., Gammon, P.T. Pharmacokinetics of isoniazid metabolism in man. Journal of Pharmacokinetics and Biopharmaceutics 4, 83–113 (1976). https://doi.org/10.1007/BF01086149

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01086149

Key words

Search

Navigation